The challenge of defining bleeding among patients with acute coronary syndromes

Clinical Cardiology

Volumn 30, Issue 10 SUPPL., 2007, Pages II-16-II-23

  Wallace, Thomas W ^a,b   Rao, Sunil V ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; Antiplatelet therapy; Bivalirudin; Bleeding definitions; Enoxaparin; Glycoprotein IIb IIIa inhibitors; Heparin

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; STREPTOKINASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; EPISTAXIS; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HEMATURIA; HEMOPTYSIS; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; REVIEW;

EID: 35348843551     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20229     Document Type: Review

References (32)

1. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, et al., TACTICS-Thrombolysis in Myocardial Infarction 18 Investigators: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887
2. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, et al.: Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005;96:1200-1206
3. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, et al.: Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114:774-782
4. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, et al., SYNERGY Trial Investigators: Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54
5. PURSUIT Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443
6. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, et al.: Thrombolysis in Myocardial Infarction (TIM1) Trial, Phase 1: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987;76:142-154
7. GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682
8. Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, et al., GRACE Investigators: Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24:1815-1823
9. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, et al., TIMI Investigators: Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11
10. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782
11. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-1505
12. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497, (erratum in N Engl J Med. 1998;339:415)
13. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators: Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999;353:429-438
14. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
15. Théroux P, Pérez-Villa F, Waters D, Lespérance J, Shabani F, et al.: Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995;91:2132-2139
16. White HD, Aylward PE, Frey MJ, Adgey AA, Nair R, et al., Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators: Randomized, double-blind comparison of Hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-2161
17. EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961
18. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, et al., HELVETICA Investigators: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-763
19. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, et al., Hirulog Angioplasty Study Investigators: Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769
20. EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696
21. RESTORE Investigators: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453
22. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, et al., ESPRIT Investigators: Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial: a randomized controlled trial. JAMA 2001;285:2468-2473
23. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, et al., REPLACE-2 Investigators: Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863, (erratum in JAMA 2003;289:1638)
24. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, et al., STEEPLE Investigators: Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-1017
25. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, et al., ACUITY Investigators: Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-2216
26. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, et al.: A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006;47:809-816
27. Mulvihill NT, Foley JB, Murphy RT, Curtin R, Crean PA, et al.: Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 2001;85:623-627
28. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, et al.: Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292:1555-1562
29. Yang X, Alexander KP, Chen AY, Roe MT, Brindis RG, et al., CRUSADE Investigators: The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE national quality improvement initiative. J Am Coll Cardiol 2005;46:1490-1495
30. Welch HG, Meehan KR, Goodnough LT: Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992;116:393-402
31. McMahon TJ, Moon RE, Luschinger BP, Carraway MS, Stone AE, et al.: Nitric oxide in the human respiratory cycle. Nat Med 2002;8:711-717
32. Fransen E, Maessen J, Dentener M, Senden N, Buurman W: Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest 1999;116:1233-1239